I figure that we'll need to spend about $192 million starting today to get to FDA approval: $4 million per month for 48 months. Subtract around $20 million cash on hand currently, $37 million from reimbursements for DurAVR's used in trials, $57 million in options that can be converted at $29 and around 2.7 million options at an average of maybe 10 bucks. That means we'll need another $51 million to get to approval if everything goes reasonably well, although cash burn could increase during the pivotal trial.
My projection has been that we'll wind up with somewhere around 25 million shares fully diluted or less when we sell our first valve post-approval and that seems reasonable as we currently have less than 21 million shares fully diluted.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)